{"id":"androderm","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Skin irritation at application site"},{"rate":"5-10","effect":"Acne"},{"rate":"5-15","effect":"Polycythemia (elevated red blood cell count)"},{"rate":"1-5","effect":"Gynecomastia (breast tissue enlargement)"},{"rate":"1-5","effect":"Headache"},{"rate":"1-5","effect":"Mood changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Androderm is a transdermal patch that provides continuous testosterone replacement therapy by delivering testosterone through the skin into systemic circulation. It is used to treat testosterone deficiency (hypogonadism) in adult males, restoring normal testosterone levels and associated physiological functions including sexual function, muscle mass, bone density, and mood.","oneSentence":"Androderm delivers testosterone transdermally to replace deficient testosterone in hypogonadal men.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:17.035Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Testosterone replacement therapy in adult males with primary or secondary hypogonadism"}]},"trialDetails":[{"nctId":"NCT06689085","phase":"PHASE3","title":"52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism","status":"RECRUITING","sponsor":"Halozyme Therapeutics","startDate":"2025-03-07","conditions":"Hypogonadism, Male","enrollment":100},{"nctId":"NCT07143279","phase":"EARLY_PHASE1","title":"Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2026-02-11","conditions":"Hypotestosteronism, Palliative Care","enrollment":20},{"nctId":"NCT06291675","phase":"","title":"Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2023-03-03","conditions":"Gender Dysphoria, Hormone Therapy Induced Morphologic Change","enrollment":50},{"nctId":"NCT06385509","phase":"PHASE4","title":"A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2024-05-10","conditions":"Hypogonadism","enrollment":110},{"nctId":"NCT03910738","phase":"PHASE2","title":"TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2019-10-29","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":40},{"nctId":"NCT05249634","phase":"PHASE2","title":"Testosterone Treatment in Men with Chronic Kidney Disease","status":"RECRUITING","sponsor":"St. Louis University","startDate":"2022-03-15","conditions":"Hypogonadism, Male, Kidney Disease, Chronic","enrollment":20},{"nctId":"NCT06351501","phase":"PHASE3","title":"Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering from Gender Dysphoria","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-25","conditions":"Gender Dysphoria","enrollment":60},{"nctId":"NCT03721497","phase":"PHASE4","title":"Testosterone in Bariatric Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Esbjerg Hospital - University Hospital of Southern Denmark","startDate":"2020-12-17","conditions":"Bariatric Surgery Candidate, Male Hypogonadism, Muscle Loss","enrollment":64},{"nctId":"NCT02432261","phase":"PHASE1","title":"Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men","status":"COMPLETED","sponsor":"Kimberly Myer","startDate":"2015-04","conditions":"Healthy","enrollment":44},{"nctId":"NCT02733133","phase":"PHASE2","title":"Product Transference Study of Testagen™ TDS®-Testosterone","status":"UNKNOWN","sponsor":"Transdermal Delivery Solutions Corp","startDate":"2016-11","conditions":"Hypogonadotropism","enrollment":96},{"nctId":"NCT05156606","phase":"NA","title":"Testosterone & Tamoxifen Trial","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2022-11-10","conditions":"Male Breast Cancer","enrollment":5},{"nctId":"NCT02418572","phase":"PHASE3","title":"Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial","status":"TERMINATED","sponsor":"Fundacion Dexeus","startDate":"2015-04","conditions":"Infertility, Poor Ovarian Response","enrollment":290},{"nctId":"NCT03518034","phase":"PHASE4","title":"A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-05-03","conditions":"Hypogonadism, Cardiovascular Diseases","enrollment":5246},{"nctId":"NCT01187485","phase":"PHASE1","title":"A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2004-06","conditions":"Prostate Cancer","enrollment":15},{"nctId":"NCT05825092","phase":"PHASE2","title":"Effects of Early Testosterone Gel Administration on Physical Performance in the Critically Ill","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2023-07-21","conditions":"Critical Illness","enrollment":600},{"nctId":"NCT04523480","phase":"PHASE3","title":"Testopel ® vs. Generic Testosterone Pellets.","status":"COMPLETED","sponsor":"University of Miami","startDate":"2020-03-12","conditions":"Hypogonadism","enrollment":75},{"nctId":"NCT03678233","phase":"PHASE2","title":"Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2019-06-27","conditions":"Hypermetabolism in ICU, Loss of Muscle Mass, Functional Disability After ICU","enrollment":30},{"nctId":"NCT04320745","phase":"PHASE4","title":"A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants","status":"COMPLETED","sponsor":"Allergan","startDate":"2020-05-19","conditions":"Hypogonadism","enrollment":168},{"nctId":"NCT00612742","phase":"PHASE3","title":"Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women","status":"COMPLETED","sponsor":"BioSante Pharmaceuticals","startDate":"2008-01","conditions":"Hypoactive Sexual Desire Disorder","enrollment":3656},{"nctId":"NCT04757532","phase":"PHASE1","title":"Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2020-12-03","conditions":"Healthy Volunteers","enrollment":9},{"nctId":"NCT03578497","phase":"PHASE2","title":"Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2018-08-31","conditions":"Polycystic Ovary Syndrome","enrollment":18},{"nctId":"NCT03815331","phase":"PHASE4","title":"Xiaflex® Plus Testosterone Treatment Pilot Study Protocol","status":"COMPLETED","sponsor":"Men's Health Boston","startDate":"2019-01-14","conditions":"Peyronie's Disease (PD)","enrollment":20},{"nctId":"NCT04207684","phase":"PHASE1","title":"Generation of Biological Samples Positive to Testosterone for Anti-doping Control","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2020-02-04","conditions":"Healthy Volunteers","enrollment":4},{"nctId":"NCT03379012","phase":"PHASE2","title":"Testosterone in Metastatic Renal Cell Carcinoma Patients","status":"COMPLETED","sponsor":"Kidney Cancer Research Bureau","startDate":"2016-02-08","conditions":"Metastatic Renal Cell Carcinoma","enrollment":60},{"nctId":"NCT02233751","phase":"PHASE1","title":"Pharmacokinetic Study of Subcutaneous Testosterone Enanthate","status":"COMPLETED","sponsor":"Antares Pharma Inc.","startDate":"2014-09","conditions":"Hypogonadism","enrollment":12},{"nctId":"NCT00799617","phase":"PHASE3","title":"The Testosterone Trials in Older Men","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-11","conditions":"Andropause","enrollment":790},{"nctId":"NCT00975650","phase":"PHASE2","title":"Efficacy and Tolerability of an Intra-Nasal Testosterone Product","status":"COMPLETED","sponsor":"Acerus Pharmaceuticals Corporation","startDate":"2009-08","conditions":"Hypogonadism","enrollment":57},{"nctId":"NCT02504541","phase":"PHASE3","title":"Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism","status":"COMPLETED","sponsor":"Antares Pharma Inc.","startDate":"2015-07","conditions":"Hypogonadism","enrollment":133},{"nctId":"NCT02777242","phase":"PHASE2","title":"Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism","status":"COMPLETED","sponsor":"Antares Pharma Inc.","startDate":"2016-06","conditions":"Hypogonadism","enrollment":66},{"nctId":"NCT00705796","phase":"PHASE1","title":"Influence of Administration Route of Testosterone on Male Fertility","status":"WITHDRAWN","sponsor":"Acerus Pharmaceuticals Corporation","startDate":"","conditions":"Hypogonadism","enrollment":""},{"nctId":"NCT02159469","phase":"PHASE3","title":"Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism","status":"COMPLETED","sponsor":"Antares Pharma Inc.","startDate":"2014-07","conditions":"Hypogonadism","enrollment":150},{"nctId":"NCT01813201","phase":"PHASE4","title":"Benefit of the Treatment With Testosterone in Chronic Heart Failure Testosterone Deficiency Subjects","status":"COMPLETED","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2011-03","conditions":"Heart Failure","enrollment":14},{"nctId":"NCT00240981","phase":"PHASE4","title":"TOM: Testosterone in Older Men With Sarcopenia","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2005-01","conditions":"Sarcopenia, Hypogonadism, Muscular Diseases","enrollment":209},{"nctId":"NCT00853697","phase":"PHASE2","title":"Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-03","conditions":"Prostate Cancer, Castration-resistant, Metastatic","enrollment":6},{"nctId":"NCT00706719","phase":"PHASE2","title":"To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone","status":"COMPLETED","sponsor":"Repros Therapeutics Inc.","startDate":"2008-06","conditions":"Secondary Hypogonadism","enrollment":17},{"nctId":"NCT00848497","phase":"EARLY_PHASE1","title":"Testosterone for Penile Rehabilitation After Radical Prostatectomy","status":"TERMINATED","sponsor":"Mohit Khera","startDate":"2007-11","conditions":"Hypogonadism, Erectile Dysfunction","enrollment":3},{"nctId":"NCT01292785","phase":"","title":"Effects of Sex Steroid Hormones on Human Brain Function, Structure and Connectivity","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2011-01","conditions":"Gender Identity Disorder","enrollment":80},{"nctId":"NCT01689896","phase":"PHASE4","title":"Testosterone and Pain Sensitivity","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2012-08","conditions":"Low Testosterone, Hypogonadism, Pain","enrollment":""},{"nctId":"NCT00551785","phase":"","title":"Surveillance Study of Women Taking Intrinsa®","status":"TERMINATED","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2007-09","conditions":"Ovariectomy, Hysterectomy, Hypoactive Sexual Desire Disorder","enrollment":328},{"nctId":"NCT00141570","phase":"PHASE2","title":"Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2004-06","conditions":"Menopause","enrollment":350},{"nctId":"NCT02004132","phase":"PHASE1","title":"A Study of Axiron® in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-12","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT01065220","phase":"PHASE4","title":"Sex Steroids and the Serotonin Transporter","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2010-02","conditions":"Transsexualism","enrollment":32},{"nctId":"NCT00847314","phase":"","title":"Efficacy and Tolerability of Testogel/Nebido in Combination With Exercise and Diet in Hypogonadal Male Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-06","conditions":"Hypogonadism","enrollment":30},{"nctId":"NCT00613002","phase":"PHASE3","title":"Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women","status":"COMPLETED","sponsor":"BioSante Pharmaceuticals","startDate":"2006-12","conditions":"Hypoactive Sexual Desire Disorder","enrollment":597},{"nctId":"NCT00657501","phase":"PHASE3","title":"Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women","status":"COMPLETED","sponsor":"BioSante Pharmaceuticals","startDate":"2008-03","conditions":"Hypoactive Sexual Desire Disorder","enrollment":575},{"nctId":"NCT01148433","phase":"","title":"Quality of Life With TESTIM®","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2010-05","conditions":"Hypogonadism","enrollment":157},{"nctId":"NCT01143818","phase":"","title":"ESPRIT Study in Hypogonadal Men","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-12","conditions":"Hypogonadism","enrollment":1053},{"nctId":"NCT00702650","phase":"PHASE3","title":"A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-06","conditions":"Hypogonadism","enrollment":155},{"nctId":"NCT01096329","phase":"PHASE1","title":"A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®","status":"TERMINATED","sponsor":"VIVUS LLC","startDate":"2010-02","conditions":"Hypoactive Sexual Desire Disorder","enrollment":16},{"nctId":"NCT00857961","phase":"PHASE2","title":"A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-10","conditions":"Hypogonadism","enrollment":21},{"nctId":"NCT00857454","phase":"PHASE3","title":"A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-10","conditions":"Hypogonadism","enrollment":71},{"nctId":"NCT00410306","phase":"","title":"Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-10","conditions":"Male, Hypogonadism","enrollment":1493},{"nctId":"NCT00838838","phase":"","title":"Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-09","conditions":"Hypogonadism, Paraplegia, Bone Density","enrollment":26},{"nctId":"NCT00962637","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism","status":"COMPLETED","sponsor":"Repros Therapeutics Inc.","startDate":"2006-03","conditions":"Secondary Hypogonadism","enrollment":194},{"nctId":"NCT00141544","phase":"PHASE2","title":"The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women","status":"TERMINATED","sponsor":"Solvay Pharmaceuticals","startDate":"2004-07","conditions":"Menopause","enrollment":28},{"nctId":"NCT00141557","phase":"PHASE2","title":"The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women","status":"TERMINATED","sponsor":"Solvay Pharmaceuticals","startDate":"2004-07","conditions":"Menopause","enrollment":133},{"nctId":"NCT00623116","phase":"NA","title":"A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland","status":"UNKNOWN","sponsor":"Hospital for Children and Adolescents, Finland","startDate":"2007-12","conditions":"Kallmann Syndrome","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Androderm®","genericName":"Androderm®","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Androderm delivers testosterone transdermally to replace deficient testosterone in hypogonadal men. Used for Testosterone replacement therapy in adult males with primary or secondary hypogonadism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}